

IN THE CLAIMS:

Please replace all prior versions of claims 10-28 with the version of claims 10-28 set forth below:

1.-9. (Canceled).

10. (Currently Amended) A vaccine composition comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits of heat-labile enterotoxin ~~characteristic~~ of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, ~~and~~ wherein said at least one ~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

11. (Previously Presented) The vaccine composition according to claim 10, wherein said B subunits are prepared by recombinant DNA methods.

12. (Currently Amended) The vaccine composition according to claim 10 or claim 11, wherein the at least one ~~particulate~~ immunogen comprises a viral antigen, a bacterial antigen, or a fungal antigen, or a combination thereof.

13. (Currently Amended) The vaccine composition according to claim 10, wherein the at least one ~~particulate~~ immunogen is ~~derived~~ from at least one infective agent which causes a disease which is transmitted by mucosal infection.

14. (Currently Amended) The vaccine composition according to claim 10, wherein the at least one ~~particulate~~ immunogen is ~~characteristic of~~ from a micro-organism which causes a disease which is transmitted by mucosal infection.

15. (Currently Amended) The vaccine composition according to claim 10 or claim 11, wherein the at least one ~~particulate~~ immunogen provides immunization against a disease which is transmitted by mucosal infection.

16. (Currently Amended) The vaccine composition according to claim 15, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

17. (Currently Amended) A method for the induction of a systemic immunoglobulin response against at least one immunogen in a human or animal host in need of such induction, comprising:

administering to mucosal tissue of the host said at least one immunogen in the ~~particulate~~ form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile

enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction, and wherein said at least one immunogen is not covalently coupled to said B subunits.

18. (Currently Amended) A method for ~~the induction of a common mucosal immune response~~ activating the common mucosal immune system against at least one immunogen in a human or animal host in need of such ~~induction~~ activating, comprising:
administering to mucosal tissue of the host said at least one immunogen in the particulate form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said ~~induction~~ activating, and wherein said at least one immunogen is not covalently coupled to said B subunits.

19. (Currently Amended) A method of preparing a vaccine for the induction of a systemic immunoglobulin response against at least one immunogen in a human or animal host upon mucosal administration of said vaccine, comprising:
combining said at least one immunogen in the particulate form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E.*

coli, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction, and wherein said at least one immunogen is not covalently coupled to said B subunits.

20. (Currently Amended) A method of preparing a vaccine for ~~the induction of a common mucosal immune response~~ activating the common mucosal immune system against at least one immunogen in a human or animal host upon local mucosal administration of said vaccine, comprising:

combining said at least one immunogen in the particulate form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile enterotoxin ~~characteristic of E. coli~~, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said ~~induction~~ activating, and wherein said at least one immunogen is not covalently coupled to said B subunits.

21. (Currently Amended) A vaccine comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits of enterotoxin, wherein said B subunits are free of A subunit and toxic LT holotoxin, ~~and~~ wherein said at least one ~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at

least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

22. (Currently Amended) A vaccine comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits of cholera toxin, wherein said B subunits are free of A subunit and toxic CT holotoxin, ~~and~~ wherein said at least one ~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

23. (Currently Amended) A vaccine comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits chosen from enterotoxin and cholera toxin, wherein said B subunits are free of A subunit, toxic LT holotoxin, and toxic CT holotoxin, ~~and~~ wherein said at least one ~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

24. (Currently Amended) The vaccine according to claim 21, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

25. (Currently Amended) The vaccine according to claim 22, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

26. (Currently Amended) The vaccine according to claim 23, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

27. (Currently Amended) The vaccine composition of claim 10, wherein the at least one ~~particulate~~ immunogen comprises micelles, rosettes, or a mixture of micelles and rosettes.

28. (Currently Amended) The vaccine of any one of claim 21, claim 22, and claim 23, wherein the at least one ~~particulate~~ immunogen comprises micelles, rosettes, or a mixture of micelles and rosettes.